Work did not slow down at Naurex after its acquisition by Allergan for $560m up front – a return of at least 3.4 times the $163m in venture capital invested in the company – since the underlying technology platform was spun out in a new firm, which launched on Sept. 16 as Aptinyx.
Aptinyx retained the entire Naurex management team and staff, including president and CEO Norbert Riedel, who told Scrip that Naurex's investors provided seed funding to support Aptinyx until the new company is able to close a Series A venture capital financing round
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?